Insider filing · RLMD

Sergio Traversa bought $600K of Relmada Therapeutics (RLMD)

Executed Nov 5 2025, disclosed Nov 6 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Nov 6 2025), the stock returned +48.8% (delay-adjusted); from the execution session (Nov 5 2025), +56.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

ST Sergio Traversa Chief Executive Officer profile →

Sergio Traversa (Chief Executive Officer) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 2 priced purchase filings, the average 21-session return was +25.0% from execution and +18.3% from disclosure (delay-adjusted; derived). The largest single filing was $828K of RLMD (200,000 sh across 2 lots, as filed), executed Sep 9.

RLMD Relmada Therapeutics, Inc. RLMD · Healthcare · 8 filings in 24 months ticker →

Healthcare · Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→